Paraneoplastic Syndromes - 51 Studies Found
Recruiting |
: Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes : Myasthenic Syndromes, Congenital : 2015-09-24 :
|
Available |
: Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients :
: 2013-01-06 :
|
Available |
: Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome :
: 2011-12-24 :
|
Completed |
: Pregnancy Outcomes in Congenital Myasthenie Syndrome : Congenital Myasthenic Syndrome : 2011-11-16 |
No longer available |
: Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP : Lambert Eaton Myasthenic Syndrome (LEMS) : 2011-06-20 : Drug: 3,4-diaminopyridine Treatment will begin with 5mg three times a day or less. |
Completed |
: A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) : Lambert Eaton Myasthenic Syndrome : 2011-06-17 :
|
No longer available |
: Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome : Lambert-Eaton Myasthenic Syndrome : 2011-06-13 : Drug: 3,4 DAP Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per da |
Completed |
: MC-5A for Chemotherapy Induced Peripheral Neuropathy : Neuropathy, Paraneoplastic : 2010-12-09 :
|